American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
 - EconoTimes)
NEW YORK, Jan. 18, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Ophthotech Corporation (“Ophthotech” or the “Company”) (NASDAQ:OPHT) in the United States District Court for the Southern District of Indiana on behalf of purchasers of common stock of Ophthotech between May 11, 2015 and December 12, 2016 (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
According to the Complaint, Defendants made overtly positive representations regarding the effectiveness of its treatment Fovista and Fovista’s potential when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent. According to the Complaint, Ophthotech made these statements despite its awareness that the phase 3 clinical trial of Fovista would not meet its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The Complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech released its discouraging results for two phase 3 clinical trials that were testing its experimental compound Fovista combined with the Lucentis drug. Following this news, Ophthotech stock dropped close to 86% during to close at $5.29 per share.
If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
